Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain

BOSTON--(BUSINESS WIRE)--Apr. 18, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials